Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Has Average Target Price of $802.18

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) have received a consensus recommendation of “Moderate Buy” from the twenty-six research firms that are covering the firm, Marketbeat Ratings reports. Nine analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $809.50.

Several equities research analysts have recently issued reports on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, September 21st. HSBC upped their price target on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Royal Bank Of Canada restated a “sector perform” rating and set a $737.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 29th. Wall Street Zen raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, September 20th. Finally, Argus upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $850.00 target price for the company in a research note on Thursday.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Sanofi alliance expanded, with substantial upfront and milestone potential. Sanofi will pay Regeneron $1 billion upfront and up to $7 billion in additional milestones for four next-generation, long-acting antibodies targeting type 2 inflammation. The companies will share development and commercialization costs and future profits, strengthening Regeneron’s immunology pipeline beyond Dupixent. Sanofi pays Regeneron up to $8B to expand immunology alliance
• Positive Sentiment: Weight-loss combination data address a key GLP-1 concern. In the Phase 2 COURAGE trial, trevogrumab preserved approximately 70% of the muscle lost by patients receiving semaglutide alone in an MRI substudy. The result could give Regeneron a differentiated position in the obesity market, although additional development and regulatory work remain. Phase 2 COURAGE Trial results
• Positive Sentiment: Analysts became more constructive. Jefferies raised its price target to $930 and maintained a buy rating, while Argus upgraded REGN to buy with an $850 target. These actions suggest improved confidence in the company’s pipeline and longer-term growth prospects.
• Neutral Sentiment: Ubamatamab showed promising but early oncology results. The therapy produced a 73% objective response rate and 11-month median progression-free survival in 11 heavily pretreated patients with low-grade serous ovarian cancer. The small, early-stage dataset is encouraging but requires confirmation in larger studies. Ubamatamab ovarian cancer study
• Negative Sentiment: Investors appeared underwhelmed by the ovarian cancer data. Despite the high response rate, reports indicated that REGN came under pressure after the early-stage readout, likely reflecting concerns about the limited patient sample, durability, and the distance to possible approval.

Insider Activity

In other news, EVP Marion Mccourt sold 1,131 shares of the firm’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $857.39, for a total transaction of $969,708.09. Following the completion of the sale, the executive vice president directly owned 12,003 shares in the company, valued at $10,291,252.17. This trade represents a 8.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at approximately $1,362,400. This trade represents a 31.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 3,946 shares of company stock worth $3,302,458 over the last 90 days. Company insiders own 6.97% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of institutional investors have recently made changes to their positions in REGN. CX Institutional grew its position in shares of Regeneron Pharmaceuticals by 30.1% during the third quarter. CX Institutional now owns 501 shares of the biopharmaceutical company’s stock worth $380,000 after buying an additional 116 shares in the last quarter. Versant Capital Management Inc grew its holdings in Regeneron Pharmaceuticals by 55.2% during the 3rd quarter. Versant Capital Management Inc now owns 534 shares of the biopharmaceutical company’s stock worth $405,000 after acquiring an additional 190 shares in the last quarter. Envestnet Asset Management Inc. increased its position in shares of Regeneron Pharmaceuticals by 0.6% in the 2nd quarter. Envestnet Asset Management Inc. now owns 109,838 shares of the biopharmaceutical company’s stock worth $68,488,000 after purchasing an additional 686 shares during the last quarter. Andra AP fonden raised its stake in shares of Regeneron Pharmaceuticals by 583.2% in the 2nd quarter. Andra AP fonden now owns 28,912 shares of the biopharmaceutical company’s stock valued at $18,028,000 after purchasing an additional 24,680 shares in the last quarter. Finally, State Street Corp grew its stake in Regeneron Pharmaceuticals by 3.6% in the second quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock worth $3,014,621,000 after purchasing an additional 170,210 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $735.20 on Wednesday. The company has a market cap of $75.70 billion, a price-to-earnings ratio of 18.17, a price-to-earnings-growth ratio of 1.41 and a beta of 0.16. Regeneron Pharmaceuticals has a 12 month low of $541.00 and a 12 month high of $859.34. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The stock’s 50-day moving average is $788.30 and its 200-day moving average is $720.68.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The business had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. During the same quarter in the previous year, the business earned $12.81 EPS. The company’s revenue for the quarter was up 16.7% on a year-over-year basis. Equities analysts anticipate that Regeneron Pharmaceuticals will post 45.34 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were given a $0.94 dividend. The ex-dividend date of this dividend was Tuesday, August 18th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.29%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.